Sigyn Therapeutics (OTCMKTS:SIGY) Shares Up 5.3% – Should You Buy?

Sigyn Therapeutics, Inc. (OTCMKTS:SIGYGet Free Report) shot up 5.3% during mid-day trading on Thursday . The company traded as high as $2.00 and last traded at $2.00. 154 shares were traded during trading, a decline of 55% from the average session volume of 345 shares. The stock had previously closed at $1.90.

Sigyn Therapeutics Stock Performance

The company has a 50-day moving average of $2.78 and a 200-day moving average of $2.96. The stock has a market cap of $3.22 million, a price-to-earnings ratio of -0.42 and a beta of -0.88.

Sigyn Therapeutics Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, November 21st. Stockholders of record on Friday, October 24th will be paid a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a dividend yield of 64.0%. The ex-dividend date is Friday, October 24th.

About Sigyn Therapeutics

(Get Free Report)

Sigyn Therapeutics, Inc, a development-stage company, provides therapeutic solutions in the United States. Its lead product candidate is Sigyn Therapy, a broad-spectrum blood purification technology designed to treat pathogen-associated inflammatory disorders, including endotoxemia and inflammation in end-stage renal disease patients, sepsis, community acquired pneumonia, drug resistant bacterial infections, and emerging pandemic threats.

Featured Articles

Receive News & Ratings for Sigyn Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sigyn Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.